Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8917606 | 0.99 | TACR1 (0.48) | TACR1CYP2D6TP53CYP1A2CYP3A4 | |
| SCHEMBL14414161 | 0.74 | TACR1 (0.52) | TACR1CYP2D6 | |
| SCHEMBL7168080 | 0.74 | TACR1 (0.49) | TACR1CYP2D6 | |
| SCHEMBL3373697 | 0.73 | TACR1 (0.57) | TACR1 | |
| SCHEMBL7250070 | 0.73 | TACR1 (0.54) | TACR1CYP2D6 | |
| SCHEMBL4917005 | 0.71 | TACR1 (0.77) | TACR1CYP2D6 | |
| Hydrochloric Acid SCHEMBL4914589 | 0.70 | TACR1 (0.75) | TACR1CYP2D6 | |
| SCHEMBL6699054 | 0.69 | TACR1 (0.70) | TACR1CYP2D6 | |
| SCHEMBL8630684 | 0.69 | TACR1 (0.48) | TACR1CYP2D6 | |
| SCHEMBL8630688 | 0.69 | TACR1 (0.48) | TACR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027892-B1 | Azithromycin combination for emesis control in dogs | PFIZER PROD INC (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040063649-A1 | Azithromycin combination for emesis control in mammals | PFIZER INC | 2004-04-01 | — | — | US | claimed |
| US-20030018049-A1 | Azithromycin combination for emesis control in mammals | GODEK DENNIS M (US) | 2003-01-23 | — | — | US | claimed |
| US-20020016301-A1 | Azithromycin combination for emesis control in mammals | GODEK DENNIS M (US) | 2002-02-07 | — | — | US | claimed |
| EP-1027892-A2 | Azithromycin combination for emesis control in dogs | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| EP-0854720-B1 | NK-1 RECEPTOR ANTAGONISTS FOR PREVENTION OF NEUROGENIC INFLAMMATION IN GENE THERAPY | PFIZER (US) | 1999-08-04 | — | — | EP | claimed |
| EP-0773026-A2 | NK-1 receptor antagonists for the treatment of cancer | PFIZER INC. (US) | 1997-05-14 | — | — | EP | claimed |
| EP-0659409-A2 | Substance 1 antagonists for the inhibition of angiogenesis | PFIZER INC. (US) | 1995-06-28 | — | — | EP | claimed |
| EP-0655246-A1 | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria | PFIZER INC. (US) | 1995-05-31 | — | — | EP | claimed |
| US-5393762-A | Pharmaceutical agents for treatment of emesis | PFIZER INC. (US) | 1995-02-28 | — | — | US | claimed |
| EP-0627221-A2 | Substance P antagonists for the treatment of emesis | PFIZER INC. (US) | 1994-12-07 | — | — | EP | claimed |
| US-5340826-A | Pharmaceutical agents for treatment of urinary incontinence | PFIZER INC. (US) | 1994-08-23 | — | — | US | claimed |
| EP-1027892-B1 | Azithromycin combination for emesis control in dogs | PFIZER PROD INC (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040063649-A1 | Azithromycin combination for emesis control in mammals | PFIZER INC | 2004-04-01 | — | — | US | disclosed |
| US-20030018049-A1 | Azithromycin combination for emesis control in mammals | GODEK DENNIS M (US) | 2003-01-23 | — | — | US | disclosed |
| US-20020016301-A1 | Azithromycin combination for emesis control in mammals | GODEK DENNIS M (US) | 2002-02-07 | — | — | US | disclosed |
| EP-0655246-A1 | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria | PFIZER INC. (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5393762-A | Pharmaceutical agents for treatment of emesis | PFIZER INC. (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0627221-A2 | Substance P antagonists for the treatment of emesis | PFIZER INC. (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5340826-A | Pharmaceutical agents for treatment of urinary incontinence | PFIZER INC. (US) | 1994-08-23 | — | — | US | disclosed |